Gebhart, G., Keyaerts, M., Guiot, T., Flamen, P., Ruiz-Borrego, M., Stradella, A., . . . Llombart-Cussac, A. (2024). Optimal (18F)FDG PET/CT cutoff for pathologic complete response in HER2-positive early breast cancer patients treated with neoadjuvant trastuzumab and pertuzumab in the PHERgain trial. Journal of nuclear medicine, 65(5), . https://doi.org/10.2967/jnumed.123.266384
Chicago Style (17th ed.) CitationGebhart, Geraldine, et al. "Optimal (18F)FDG PET/CT Cutoff for Pathologic Complete Response in HER2-positive Early Breast Cancer Patients Treated with Neoadjuvant Trastuzumab and Pertuzumab in the PHERgain Trial." Journal of Nuclear Medicine 65, no. 5 (2024). https://doi.org/10.2967/jnumed.123.266384.
MLA (9th ed.) CitationGebhart, Geraldine, et al. "Optimal (18F)FDG PET/CT Cutoff for Pathologic Complete Response in HER2-positive Early Breast Cancer Patients Treated with Neoadjuvant Trastuzumab and Pertuzumab in the PHERgain Trial." Journal of Nuclear Medicine, vol. 65, no. 5, 2024, https://doi.org/10.2967/jnumed.123.266384.